CO2017000443A2 - Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa - Google Patents

Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa

Info

Publication number
CO2017000443A2
CO2017000443A2 CONC2017/0000443A CO2017000443A CO2017000443A2 CO 2017000443 A2 CO2017000443 A2 CO 2017000443A2 CO 2017000443 A CO2017000443 A CO 2017000443A CO 2017000443 A2 CO2017000443 A2 CO 2017000443A2
Authority
CO
Colombia
Prior art keywords
imidazol
pyran
synthase inhibitors
aldosterone synthase
compounds
Prior art date
Application number
CONC2017/0000443A
Other languages
English (en)
Inventor
Maolin Yu
Jennifer Burke
Derek Cogan
John Lord
Daniel Richard Marshall
Bryan P Mckibben
Yunlong Zhang
Matthew A Cerny
Lee Fader
Kosea S Frederick
Simon Surprenant
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO2017000443A2 publication Critical patent/CO2017000443A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a los compuestos de la Fórmula I: y a las sales de estos aceptables desde el punto de vista farmacéutico, en donde Cy, R1 y R2 son como se definen en la presente. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, a métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, a procesos para preparar estos compuestos y a intermediarios útiles en estos procesos.
CONC2017/0000443A 2014-07-24 2017-01-19 Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa CO2017000443A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028556P 2014-07-24 2014-07-24
PCT/US2015/041648 WO2016014736A1 (en) 2014-07-24 2015-07-23 Aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
CO2017000443A2 true CO2017000443A2 (es) 2017-04-10

Family

ID=53761616

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0000443A CO2017000443A2 (es) 2014-07-24 2017-01-19 Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa

Country Status (34)

Country Link
US (1) US9334285B2 (es)
EP (1) EP3172212B1 (es)
JP (1) JP6250862B2 (es)
KR (1) KR102378648B1 (es)
CN (1) CN106488921B (es)
AP (1) AP2016009616A0 (es)
AR (1) AR101290A1 (es)
AU (1) AU2015292632B2 (es)
BR (1) BR112017000584B1 (es)
CA (1) CA2956118C (es)
CL (1) CL2017000040A1 (es)
CO (1) CO2017000443A2 (es)
CY (1) CY1121063T1 (es)
DK (1) DK3172212T3 (es)
EA (1) EA031105B1 (es)
ES (1) ES2684050T3 (es)
HR (1) HRP20181441T1 (es)
HU (1) HUE039981T2 (es)
IL (1) IL249665B (es)
LT (1) LT3172212T (es)
MX (1) MX368093B (es)
MY (1) MY191352A (es)
NZ (1) NZ727188A (es)
PE (1) PE20170294A1 (es)
PH (1) PH12017500089A1 (es)
PL (1) PL3172212T3 (es)
PT (1) PT3172212T (es)
RS (1) RS57570B1 (es)
SG (1) SG11201700595RA (es)
SI (1) SI3172212T1 (es)
TW (1) TWI600658B (es)
UA (1) UA118801C2 (es)
UY (1) UY36228A (es)
WO (1) WO2016014736A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207039B1 (en) * 2014-10-15 2019-03-06 Boehringer Ingelheim International GmbH Aldosterone synthase inhibitors
JP6707084B2 (ja) * 2014-12-02 2020-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
JP6914974B2 (ja) 2016-06-28 2021-08-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US8153674B2 (en) * 2006-03-29 2012-04-10 Novartis Ag Organic compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones

Also Published As

Publication number Publication date
EP3172212B1 (en) 2018-06-13
AU2015292632B2 (en) 2019-11-21
TW201619165A (zh) 2016-06-01
HRP20181441T1 (hr) 2018-11-02
UA118801C2 (uk) 2019-03-11
AP2016009616A0 (en) 2016-12-31
US9334285B2 (en) 2016-05-10
KR20170032459A (ko) 2017-03-22
LT3172212T (lt) 2018-08-27
CA2956118C (en) 2022-11-15
JP6250862B2 (ja) 2017-12-20
PL3172212T3 (pl) 2018-11-30
MX368093B (es) 2019-09-19
PT3172212T (pt) 2018-10-08
BR112017000584B1 (pt) 2022-07-26
EP3172212A1 (en) 2017-05-31
IL249665A0 (en) 2017-02-28
KR102378648B1 (ko) 2022-03-28
AU2015292632A1 (en) 2016-12-22
EA031105B1 (ru) 2018-11-30
MY191352A (en) 2022-06-18
BR112017000584A2 (pt) 2017-11-07
NZ727188A (en) 2020-01-31
PE20170294A1 (es) 2017-04-12
HUE039981T2 (hu) 2019-02-28
PH12017500089B1 (en) 2017-05-22
AR101290A1 (es) 2016-12-07
ES2684050T3 (es) 2018-10-01
JP2017521466A (ja) 2017-08-03
SI3172212T1 (sl) 2018-10-30
WO2016014736A1 (en) 2016-01-28
CA2956118A1 (en) 2016-01-28
EA201790253A1 (ru) 2017-07-31
CY1121063T1 (el) 2019-12-11
IL249665B (en) 2019-08-29
CN106488921A (zh) 2017-03-08
TWI600658B (zh) 2017-10-01
DK3172212T3 (en) 2018-08-27
UY36228A (es) 2016-01-29
SG11201700595RA (en) 2017-02-27
US20160024105A1 (en) 2016-01-28
CL2017000040A1 (es) 2017-07-07
RS57570B1 (sr) 2018-10-31
MX2017000929A (es) 2017-05-04
PH12017500089A1 (en) 2017-05-22
CN106488921B (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
CL2015000019A1 (es) Composicion farmaceutica que comprende rifaximina cristalina, polimorfa o amorfa, como un hidrato o solvato y/o en una mezcla de la misma y uno o mas aminoacidos; procedimiento de preparacion de la composicion; cristales de rifaximina; su procedimiento de preparacion.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
CU20170007A7 (es) Compuestos de imidazopiridazina
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
CR20160600A (es) Quinolizione derivados como inhibidores pi3k
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
ECSP18056196A (es) Derivados de indano
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida